HOME >> MEDICINE >> NEWS
Oral Biology Research Award presented to Russell

The 2007 Research in Oral Biology Award will be presented today to Dr. Michael Russell, Professor, Department of Microbiology/Immunology/Oral Biology, at the State University of New YorkBuffalo, as well as Associate Director of the Witebsky Center for Microbial Pathogenesis and Immunology.

Dr. Russell has a long and distinguished career in research in mucosal immunology and the description of the protein antigens on the bacterium most associated with dental caries, Streptococcus mutans. His studies have been well-received by the scientific community, since he has over 180 publications in prestigious journals and has been invited to present his work at more than 40 institutions around the world. He holds several patents in the area of vaccine technology. One of his most influential contributions was the discovery of an important adhesin, Antigen I/II. This discovery began a worldwide investigation into its structure and the role of this adhesin in promoting the entry of S. mutans into the oral biofilm, dental plaque. This adhesin has become one of the primary targets for immunological interventions in caries development. He also made landmark observations in the induction and sustainability of the mucosal immune response. His group was the first to apply intranasal immunization approaches to induce protective levels of antibody in the saliva. The significance of this approach is marked by the fact that, today, intranasal immunization is the route of choice for most experimental and commercial mucosal vaccines. More recently, he has opened up new research territory in studies of the mucosal immunity and vaccine development in gonorrhea.

Dr. Russell receives his award during the Opening Ceremonies of the 85th General Session of the International Association for Dental Research (IADR), convening at the Ernest N. Morial Convention Center.

The IADR Research in Oral Biology Distinguished Scientist Award, sponsored since its inception by
'"/>

Contact: Linda Hemphill
lhemphill@iadr.org
International & American Association for Dental Research
21-Mar-2007


Page: 1 2

Related medicine news :

1. Mayo Clinic research in cardiovascular disease presented at Experimental Biology 2007
2. Schmalz to receive major IADR Pulp Biology Research Award
3. Craniofacial Biology Award presented to Vargervik
4. Nanomaterials in Biology and Medicine
5. Craniofacial Biology Award presented to Mina
6. Oral Biology Research Award presented to Lamont
7. Researchers suggest TB screening for all international adoptees
8. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
9. Researchers link metal ions to neurodegenerative disease
10. RAND presents first Victor Fuchs Research Award to economists at Carnegie Mellon University
11. Wesley Research Institute study targets pharmacists to help diabetes sufferers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Oral Biology Research Award presented Russell

(Date:5/21/2013)... Boca Raton, Fla. (PRWEB) May 21, 2013 ... TV program distributed on cable networks and cable channels ... of new episodes on its YouTube channel. The producers ... profiles of companies in the shipping industry, the manufacturing ... program highlights pioneering medical facilities and medical practitioners in ...
(Date:5/21/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... relationships. With the help of Texas Counseling’s Sexuality ... of communication, and the development of healthier habits ... group workshops available for both couples and individuals ... couples enhance their relationships and learn skills to ...
(Date:5/21/2013)... Brazilian funding agency for scientific and technological research So ... So Paulo, announced an investment estimated in US$ 680 ... (RIDCs) for a period of up to eleven years, ... 7. , Funding for the 17 RIDCs will ... faculty, technicians, support personnel, and infrastructure). Host institutions will ...
(Date:5/21/2013)... Go Classy Tours, the oldest and ... redesigned their website featuring N Resort in Jamaica ... bars and dining. The website, which has always featured ... guest reviews, will now have a broader range of ... on culinary local recipes, flora and fauna, featured pictures ...
(Date:5/21/2013)... va (PRWEB) May 21, 2013 ... critical technology and management consulting solutions to the ... of Business Development. In the newly created ... leading all aspects of the firm’s business development ... and proposal management functions, and leading strategies to ...
Breaking Medicine News(10 mins):Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Research at the cutting edge of knowledge 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2
(Date:5/21/2013)... NEW YORK , May 21, 2013 ... market research report is available in its ... Global Markets and Technologies for Optical Coherence ...   STUDY OBJECTIVES ... conducting this study is to offer synopsis ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... U.S. spending on specialty prescription drugs — ... cancer, multiple sclerosis and rheumatoid arthritis — is projected ... according to a forecast released today by Express Scripts ... "As we see what,s on the ... act so they can continue to offer an affordable ...
Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5
Cached News: